Amylyx Pharmaceuticals Other Current Liabilities

As of the most recent data (March 2026), AMLX shows a other current liabilities of $11M. That compares with $12M in the prior-year period — down 6.5% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, AMLX's other current liabilities is now $11M (was $12M) — a 6.5% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Amylyx Pharmaceuticals is outperforming or lagging.

Tracking AMLX's other current liabilities over time shows whether Amylyx Pharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $11M That compares with $12M in the prior-year period — down 6.5% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this other current liabilities page, Stockcircle has Amylyx Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect other current liabilities (currently $11M) with ownership activity and broader fundamentals.